|
Health Economics
Citations 1-10 of 98 total displayed.
|
Most recent content
(1 Oct 2009):
|
- CLINICAL
Medico-economic evaluation of infliximab in rheumatoid arthritis—prospective French study of a cohort of 635 patients monitored for two years
- Jacques Sany, Jean-David Cohen, Christophe Combescure, Marie-Cécile Bozonnat, Françoise Roch-Bras, Georges Lafon, and Jean-Pierre Daurès
Rheumatology 2009; 48: 1236-1241.
[Abstract]
[Full Text]
|
Past content
(since Jan 2001):
|
- CLINICAL
Comparative cost analysis of outpatient and inpatient rehabilitation for musculoskeletal diseases in Germany
- J. Zeidler, T. Mittendorf, G. Vahldiek, H. Zeidler, and S. Merkesdal
Rheumatology 2008; 47: 1527-1534.
[Abstract]
[Full Text]
- MATTERS ARISING
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
- G. Kobelt
Rheumatology 2008; 47: 1589-1590.
[Extract]
[Full Text]
- MATTERS ARISING
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply
- A. Wailoo, N. Bansback, and J. Chilcott
Rheumatology 2008; 47: 1590-a.
[Extract]
[Full Text]
- CLINICAL
The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit
- R. M. Ara, J. C. Packham, and K. L. Haywood
Rheumatology 2008; 47: 68-71.
[Abstract]
[Full Text]
- CLINICAL
An economic evaluation of three physiotherapy treatments for non-specific neck disorders alongside a randomized trial
- M. Lewis, M. James, E. Stokes, J. Hill, J. Sim, E. Hay, and K. Dziedzic
Rheumatology 2007; 46: 1701-1708.
[Abstract]
[Full Text]
- EDITORIALS
30 million, around 10 000 ... and 18 ... Figuring out the optimal treatment for musculoskeletal conditions in the National Health Service
- D. A. Isenberg
Rheumatology 2007; 46: 1219-1220.
[Extract]
[Full Text]
- BASIC SCIENCE
Interleukin (IL)-23 p19 expression induced by IL-1ß in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor- B and AP-1 dependent pathway
- F.-L. Liu, C.-H. Chen, S.-J. Chu, J.-H. Chen, J.-H. Lai, H.-K. Sytwu, and D.-M. Chang
Rheumatology 2007; 46: 1266-1273.
[Abstract]
[Full Text]
- CLINICAL
Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom
- M. F. Botteman, J. W. Hay, M. P. Luo, A. S. Curry, R. L. Wong, and B. A. van Hout
Rheumatology 2007; 46: 1320-1328.
[Abstract]
[Full Text]
- CLINICAL
Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
- A. Brennan, N. Bansback, R. Nixon, J. Madan, M. Harrison, K. Watson, and D. Symmons
Rheumatology 2007; 46: 1345-1354.
[Abstract]
[Full Text]
|
|